Surprisingly, De Cola and colleagues have reported the upregulation of miR-205 in patient-derived breast cancer stem cells, with the consequent downregulation of Epidermal Growth Factor Receptor (EGFR) and HER2 and resistance to Lapatinib [57]. This evidence concerns the gene ERBB2 and breast cancer.